There is perhaps no better healthcare advocate than Johnson & Johnson, the world’s largest life sciences company. The pharmaceutical sector is one of the most innovative industries in Canada. The Pharmaceutical, Biotechnology and Life Sciences Sector contributes significantly to the Canadian economy by developing products and services that improve the quality of life for all Canadians.
The shift from disease management to prevention, diagnosis and treatment is attracting many interesting new players, as well as new players, from traditional pharmaceutical, biotechnology and life sciences fields. This is an exciting time for conventional players in the life sciences ecosystem and startups and investors, with significant technological advancements propelling the industry. Discoveries in the life sciences help improve the quality and standard of life and have applications in health, agriculture, medicine, pharmaceutical and food sciences.
The biotechnology industry includes companies that develop medicines and diagnostic technologies to treat diseases and conditions. Biochemistry was created by life science societies, many of which have already made substantial scientific breakthroughs.
This broad definition means that many companies fall into the life sciences category. However, due to the diversity of companies in the life sciences sector, the size of the entire market is not precisely defined.
Best Life Sciences Stocks In Canada
The global pharmaceutical market alone is worth over $1.3 trillion, and the global market for life science instruments alone (including chemicals and instruments) is valued at about $50 billion. However, since 2011, total corporate R&D spending by Canadian pharmaceutical companies has fallen below $1 billion.
Microbix Biosystems (MBX) $64.52 million 24.71% Microbix Biosystems Inc. is a life sciences company that manufactures viral and bacterial antigens and reagents for the global diagnostics industry. IntelGenx Technologies (IGX) $83.71 million 96.49% IntelGenx Technologies Corp., a pharmaceutical distribution company, is developing novel thin-film oral products for the pharmaceutical market. Abbott Laboratories sells diagnostic tools, medical equipment, food and pharmaceuticals.
Johnson & Johnson also sells pharmaceutical products, including the anti-cancer drug Imbruvik and the anti-inflammatory drug Stelara. The pharmaceutical sector comprises companies that develop and manufacture innovative medicines, generics and over-the-counter medicines. Spin will enable Johnson & Johnson to drive higher growth in the pharmaceuticals and medical devices segments.
Intuitive Surgical is likely to show solid sales growth with the launch of Trikafta/Kaftrio in Europe. Intuitive Surgical believes that new systems under development and potentially forthcoming regulatory approvals could increase the targeted soft tissue surgery market from about 6 million procedures per year to almost 20 million. While Sanofi is tight-lipped about pricing for Opdivo if approved, Sanofi has raised $1.1 billion from sales of its ERT drugs in 2020. In addition, ALKS recently partnered with Merck to develop combination therapy using Keytruda for ovarian cancer, and recent activist activity at Sarissa Capital helped boost biotech stocks by 18% last month.
Another US Food and Drug Administration approval could help blow up biotech stocks and reward shareholders. With Keytruda sales soaring, BMY needs big wins to keep Opdivo strong. In addition, there are other drug-related events planned this summer that could act as a catalyst for BMY.
That’s why the green light is so essential for ALKS on June 7th, when it’s expected to make a drug treatment decision for type 1 diabetes. Here are the best biotech stocks with the best value, fastest earnings growth and more momentum. While the beginning of the calendar year is often the best time for US Food and Drug Administration (FDA) events and experimental data, the summer also gets hot for drugmakers and biotech stocks. Finding the Prescription Drug Fee Act (PDUFA) dates, which are the deadlines for the US FDA to review a company’s drugs, and other information for several important events, can be a daunting task.
Oncology biotech company Aptose is developing several potential anticancer drugs, including investigational drug CG-806, for which the company presented promising preclinical data in December, promising preclinical data. Helix BioPharma is developing drug candidates for the prevention and treatment of cancer, including L-DOS47, its lead candidate for the treatment of non-squamous non-small cell lung cancer and pancreatic cancer. Biotech company Victoria Aurinia had a relatively quiet year until early December when the company announced positive results from its Phase 3 study of voclosporin for lupus nephritis, a condition for which there is currently no FDA-approved treatment.
Even a mid-December capital raise through a share sale did little to dampen the momentum of oncology biotech company Aptose. Canadian Life Sciences had many more losers than winners (this list includes TSX and TSX Venture, which started the year with a dime or more and excluded stocks with a market capitalization of less than $10 million). Last year, Essa Pharma also acquired the beleaguered pharmaceutical company Realm Therapeutics. In 2020, the top ten pharmaceutical companies accounted for more than half of total pharmaceutical sales in Canada, including prescription and over-the-counter drugs (IQVIA Pharmafocus 2024).
The top ten pharmaceuticals sold in Canada account for 16% of industry sales in 2020. Twenty-seven pharmaceutical and biotech companies were included in the Top 100 Corporate R&D Spending in Canada in 2019. Companies conduct research and development (R&D) to develop new or improved patented treatments, while others develop bioequivalent copies of innovative drugs after expired patents.
Pharmaceutical company Bellus Health was the top biotech company in 2018, and Bellus Health maintained its meteoric pace in 2019, achieving a compound return of 397% over the past two years.